Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 6.8% – Here’s What Happened

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) were down 6.8% on Thursday . The company traded as low as $5.67 and last traded at $5.6280. Approximately 1,886,479 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 2,872,656 shares. The stock had previously closed at $6.04.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CMPX shares. Compass Point set a $10.00 price target on Compass Therapeutics in a report on Monday, October 6th. Leerink Partnrs raised Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. Citigroup assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Citizens Jmp began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. Finally, JMP Securities set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Trading Down 1.7%

The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -12.67 and a beta of 1.45. The firm’s 50-day moving average is $5.19 and its 200 day moving average is $4.02.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently added to or reduced their stakes in CMPX. Russell Investments Group Ltd. boosted its stake in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics during the third quarter valued at $35,000. CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $37,000. Creative Planning bought a new position in shares of Compass Therapeutics in the 2nd quarter worth about $30,000. Finally, Victory Capital Management Inc. boosted its position in shares of Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.